MILAN, Sept 16 (Class Editori) - Levante Capital, the Italian investment vehicle developed in order to support the Asian expansion of European companies with high technologic content, has announced its first operation in InSilicoTrials, a project focused on accelerating the introduction of simulative computerised models in the healthcare sector.
The initial focus of the start-up will be on China and the Republic of Korea, in order to strengthen its own leader role in the Healthcare Modelling & Simulation sector at a global level.
The operation represents the launch of the investment strategy by Levante Capital, which considers the Far East as a strategic fundamental shore for those entrepreneurial initiatives which want to become global leaders. The investment includes, apart from the economic contribution, the opening of the Levante Capital large network and know-how in Asia, in order to reduce access frictions to these large markets.
InSilicoTrials is specialized in the technologies for digital clinical trials, namely those processes which allow the medical and pharmaceutical market, made up of over 60,000 companies worldwide, to create models and tests of their own solutions directly on the computer, by decreasing the times and costs related to the launch on the market of a medicine or medical product. This is an increasingly growing market, which will reach over 6.5 billion euros by 2025.
"The operation with InSilicoTrials is a strong validation of all the components of our project", as Francesco Rossi- Levante partner- has explained, "starting from the demonstration that Italian innovation is able to develop highly disruptive projects for the whole world, that the Asian market is very interested to these solutions and, lastly, that ours is a strategic role for the whole Italian and South European innovation ecosystem. Indeed, we represent the ideal way to diversify the global importance of projects, which are carried out by European visionary entrepreneurs and may benefit from a still largely unexplored destination market".
"The COVID-19 crisis has showed the limits of the current development process of therapies: it is not possible anymore to wait for years in order to have solutions", as Luca Emili- InSilicoTrials CEO- has stated. "The simulation opens futuristic scenarios, where it would become possible to accelerate by 50 percent the evaluations on molecules and thus reducing tests on animals and humans, and even testing the effectiveness and safety of personalized medical devices."
"The regulatory authorities are also supporting this approach and we are among the players which talk to each other in order to standardize its use through the GPS (Good Simulation Practices) definition. We are an Italian start-up which has already established relationships with small and big realities in Europe and the USA; therefore, having Levante Capital among our investors means opening doors towards Asia, by enjoying an easier access to a very important and constantly growing market", as the entrepreneur has concluded.
(Source:Class Editori)
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
